News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
558,324 Results
Type
Article (40578)
Company Profile (110)
Press Release (517636)
Multimedia
Podcasts (54)
Webinars (13)
Section
Business (154518)
Career Advice (2460)
Deals (28129)
Drug Delivery (102)
Drug Development (73441)
Employer Resources (141)
FDA (13765)
Job Trends (12322)
News (275100)
Policy (27318)
Tag
Academia (2565)
Academic (1)
Accelerated approval (7)
Adcomms (27)
Allergies (91)
Alliances (39357)
ALS (109)
Alzheimer's disease (1457)
Antibody-drug conjugate (ADC) (160)
Approvals (13753)
Artificial intelligence (287)
Autoimmune disease (31)
Automation (17)
Bankruptcy (313)
Best Places to Work (10020)
BIOSECURE Act (16)
Biosimilars (105)
Biotechnology (87)
Bladder cancer (92)
Brain cancer (34)
Breast cancer (345)
Cancer (2748)
Cardiovascular disease (220)
Career advice (2069)
Career pathing (32)
CAR-T (176)
CDC (28)
Cell therapy (468)
Cervical cancer (19)
Clinical research (60656)
Collaboration (880)
Company closure (3)
Compensation (377)
Complete response letters (24)
COVID-19 (2519)
CRISPR (53)
C-suite (336)
Cystic fibrosis (95)
Data (2894)
Decentralized trials (2)
Denatured (10)
Depression (70)
Diabetes (330)
Diagnostics (5835)
Digital health (18)
Diversity (5)
Diversity, equity & inclusion (39)
Drug discovery (126)
Drug pricing (120)
Drug shortages (26)
Duchenne muscular dystrophy (122)
Earnings (56479)
Editorial (42)
Employer branding (18)
Employer resources (130)
Events (77891)
Executive appointments (855)
FDA (15276)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (829)
Gene editing (123)
Generative AI (22)
Gene therapy (373)
GLP-1 (771)
Government (4230)
Grass and pollen (5)
Guidances (177)
Healthcare (16145)
Huntington's disease (30)
IgA nephropathy (42)
Immunology and inflammation (165)
Immuno-oncology (8)
Indications (37)
Infectious disease (2690)
Inflammatory bowel disease (138)
Inflation Reduction Act (13)
Influenza (61)
Intellectual property (111)
Interviews (528)
IPO (12805)
IRA (50)
Job creations (2643)
Job search strategy (1689)
Kidney cancer (15)
Labor market (31)
Layoffs (453)
Leadership (25)
Legal (5826)
Liver cancer (77)
Lung cancer (404)
Lymphoma (200)
Machine learning (10)
Management (51)
Manufacturing (324)
MASH (98)
Medical device (10695)
Medtech (10699)
Mergers & acquisitions (15958)
Metabolic disorders (824)
Multiple sclerosis (95)
NASH (23)
Neurodegenerative disease (125)
Neuropsychiatric disorders (37)
Neuroscience (2138)
NextGen: Class of 2025 (5573)
Non-profit (4023)
Now hiring (39)
Obesity (408)
Opinion (230)
Ovarian cancer (97)
Pain (104)
Pancreatic cancer (117)
Parkinson's disease (180)
Partnered (18)
Patents (282)
Patient recruitment (156)
Peanut (44)
People (51707)
Pharmaceutical (26)
Pharmacy benefit managers (14)
Phase I (18709)
Phase II (26673)
Phase III (20321)
Pipeline (1569)
Policy (193)
Postmarket research (2322)
Preclinical (7708)
Press Release (55)
Prostate cancer (132)
Psychedelics (43)
Radiopharmaceuticals (222)
Rare diseases (445)
Real estate (4234)
Recruiting (57)
Regulatory (19619)
Reports (29)
Research institute (2148)
Resumes & cover letters (360)
Rett syndrome (10)
RNA editing (8)
RSV (45)
Schizophrenia (92)
Series A (142)
Series B (97)
Service/supplier (5)
Sickle cell disease (58)
Special edition (13)
Spinal muscular atrophy (146)
Sponsored (31)
Startups (2853)
State (2)
Stomach cancer (15)
Supply chain (62)
Tariffs (47)
The Weekly (43)
Vaccines (730)
Venture capital (46)
Weight loss (256)
Women's health (35)
Worklife (17)
Date
Today (64)
Last 7 days (334)
Last 30 days (1681)
Last 365 days (27527)
2025 (14777)
2024 (30772)
2023 (34583)
2022 (45117)
2021 (48435)
2020 (46818)
2019 (39962)
2018 (30295)
2017 (27280)
2016 (26035)
2015 (30341)
2014 (22852)
2013 (18612)
2012 (20017)
2011 (20966)
2010 (18561)
Location
Africa (736)
Alabama (56)
Alaska (4)
Arizona (164)
Arkansas (11)
Asia (34322)
Australia (7143)
California (6331)
Canada (2127)
China (616)
Colorado (271)
Connecticut (248)
Delaware (175)
Europe (76645)
Florida (1001)
Georgia (205)
Hawaii (1)
Idaho (52)
Illinois (550)
India (24)
Indiana (322)
Iowa (13)
Japan (211)
Kansas (98)
Kentucky (23)
Louisiana (12)
Maine (52)
Maryland (888)
Massachusetts (4361)
Michigan (219)
Minnesota (343)
Mississippi (2)
Missouri (82)
Montana (20)
Nebraska (22)
Nevada (73)
New Hampshire (66)
New Jersey (1824)
New Mexico (20)
New York (1763)
North Carolina (899)
North Dakota (6)
Northern California (2784)
Ohio (195)
Oklahoma (7)
Oregon (27)
Pennsylvania (1333)
Puerto Rico (17)
Rhode Island (30)
South America (1002)
South Carolina (30)
South Dakota (1)
Southern California (2421)
Tennessee (102)
Texas (985)
United States (23137)
Utah (196)
Virginia (164)
Washington D.C. (60)
Washington State (540)
West Virginia (4)
Wisconsin (50)
558,324 Results for "celyad formally known as cardio3 biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BioNxt Solutions Reports Formal Notice from the European Patent Office of Intention to Grant Patent
May 23, 2025
·
3 min read
Celyad Oncology announces intention to terminate SEC reporting obligations
Celyad Oncology SA announces that it will voluntarily file a Form 15F with the United States Securities and Exchange Commission to terminate its SEC reporting obligations under Section 13 or Section 15 of the Securities Exchange Act of 1934, as amended.
February 8, 2024
·
4 min read
Business
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
Celyad Oncology (Euronext: CYAD) (the “Company”), today provides a fourth quarter 2023 business update and an outlook for 2024.
January 16, 2024
·
7 min read
Business
Celyad announces management change - December 04, 2023
Celyad Oncology announces that its CEO and managing director Georges Rawadi has decided to step down, effective as of Friday December 1, 2023.
December 4, 2023
·
3 min read
Press Releases
European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia
July 8, 2025
·
6 min read
Press Releases
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting
May 1, 2025
·
6 min read
Drug Development
Saghmos Therapeutics Announces Collaboration with Duke Clinical Research Institute to Optimize Phase 3 Cardio-Renal Metabolic Study
Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced it will partner with the Duke Clinical Research Institute (DCRI) to optimize all aspects of and plan the operationalization of Saghmos’ Phase 3 study for its cardio-renal metabolic modulator ST-62516.
April 17, 2024
·
4 min read
Business
Celyad Oncology reports third quarter 2023 financial results and recent business highlights
Celyad Oncology, a biotechnology company focused on innovative technologies for chimeric antigen receptor T-cell therapies, reports its financial results for the third quarter of 2023 and provides an update on recent business developments.
November 9, 2023
·
9 min read
Celyad Oncology announces the termination of its American Depository Receipt program
Celyad Oncology SA announces that Citibank, N.A., as depositary, shall issue the notice of terminating its American Depository Receipt program of American Depositary Shares representing ordinary shares to the holders of ADSs according to the requirements under the deposit agreement.
September 25, 2023
·
4 min read
Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
Celyad Oncology, announces its financial results and recent business developments for the first half year, ended June 30, 2023.
September 4, 2023
·
14 min read
1 of 55,833
Next
